Participant Advocacy Insights for Psychedelic Trials: UK & Global Policy Implications

Participant Experiences Highlight Gaps in Psychedelic Clinical Trials

A 2026 qualitative study by the Psychedelic Participant Advocacy Network (PsyPAN) provides direct insight into the lived experiences of former participants in psychedelic clinical trials, revealing significant gaps in support, communication, and post-trial integration (OpenAlex W7221827353). The study involved focus groups and workshops with individuals who had participated in psilocybin and N,N-dimethyltryptamine (DMT) trials for treatment-resistant depression and eating disorders. Participants reported that trial procedures—driven by eligibility criteria, randomization, blinding, and endpoint-focused protocols—often conflicted with their hopes for effective treatment and ongoing support.

Key findings show that participants entered trials seeking relief from difficult-to-treat mental health conditions, but encountered a research environment that sometimes prioritized data integrity over individual needs. The study extends the classic "set and setting" concept to encompass the unique pressures and uncertainties of the clinical trial context, including allocation uncertainty, staff conduct, and the abrupt withdrawal of support at study conclusion.

Mechanisms: Communication, Agency, and the Critical Role of Facilitators

Clear communication and participant agency emerged as central mechanisms for improving participant experience and safety in psychedelic trials. The study found that uncertainty about treatment allocation and insufficient explanation of research procedures could heighten anxiety and reduce trust. Facilitators—staff mediating between rigid protocols and participants' psychological needs—played a key role in supporting individuals during dosing sessions, helping to bridge the gap between research requirements and personal experience.

Participants emphasized the importance of continuity in staff, transparent expectation management, and explicit boundaries around touch and movement during dosing. The dosing session itself was not perceived as a discrete event, but as the beginning of an ongoing process of meaning-making and change, underscoring the need for structured integration support beyond the trial period.

Policy and Research Implications: Toward Participant-Informed Trial Design

Participant-informed practices should be integrated into the design and delivery of psychedelic clinical trials to enhance both ethical standards and data quality. The study's recommendations include:

• Clear, ongoing communication about trial procedures, risks, and the distinction between research and treatment.
• Reduced avoidable participant burden and more flexible scheduling where possible.
• Greater participant agency in trial processes and involvement of personal support networks.
• Staff continuity and training in relational, trauma-informed care.
• Structured planning for integration and study ending, including independent, trial-specific peer support groups.

These recommendations align with evolving guidance from regulatory agencies such as the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA), which increasingly emphasize patient engagement in trial design. However, the study uniquely highlights the emotional and practical challenges faced by participants after trial completion—a stage often overlooked in current protocols.

Risks, Unknowns, and Real-World Barriers

Failure to address participant needs in psychedelic trials can undermine both participant safety and the validity of trial data, as distress or disengagement may affect outcomes and retention. The study documents experiences of loss, grief, and frustration after trial completion, with limited access to psychedelically informed care in the community. Notably, participants advocated for independent peer support structures, which could mitigate risks of post-trial psychological distress but raise questions about standardization, funding, and regulatory oversight.

Resource constraints, regulatory requirements, and the need for scientific rigor present real-world barriers to implementing all participant recommendations. For example, maintaining staff continuity and offering long-term integration support may be challenging for sponsors operating under fixed budgets and timelines. However, the study suggests that even modest improvements in communication and expectation management could substantially enhance participant well-being and public trust.

Looking Forward: Integrating Lived Experience into Psychedelic Research

Incorporating participant perspectives into the design and conduct of psychedelic clinical trials is essential for ethical progress and public acceptance as these therapies move toward broader clinical use. This study from PsyPAN provides a concrete, participant-driven blueprint for improvement, emphasizing the need for structured post-trial support and clearer distinction between research and therapy. As regulators and sponsors consider these recommendations, the field faces a pivotal decision: whether to treat participant advocacy as a compliance burden or as a source of innovation that can improve both safety and scientific outcomes.

Byline: Dr. Eleanor James, PhD (Clinical Psychology), reviewed by Dr. Samuel Osei, MD, MRCPsych, on 2026-10-17. Research based on primary analysis of OpenAlex W7221827353 and direct review of participant advocacy recommendations.